Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-06-22Clinical Trial Update: Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. [Phase 3]
A Phase 3 pilot trial evaluating grazoprevir plus elbasvir for 12 or 16 weeks in liver transplant recipients with hepatitis C has been withd…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection [Phase 3]
This document reports a termination of a long-term follow-up Phase 3 study of a regimen containing odalasvir, AL-335, with or without simepr…
-
EMA withdrawal · 2024-10-02EMA Withdrawn: Viekirax (ombitasvir;paritaprevir;ritonavir) — AbbVie Deutschland GmbH & Co. KG
The EMA has withdrawn the marketing authorization for Viekirax (ombitasvir/paritaprevir/ritonavir) for chronic hepatitis C.
-
EMA withdrawal · 2024-10-01EMA Withdrawn: Exviera (dasabuvir sodium) — AbbVie Ltd
The European Medicines Agency has withdrawn Exviera (dasabuvir sodium) from the market; it was used to treat chronic hepatitis C.
-
CLINICAL_TRIALS withdrawal · 2022-08-31Clinical Trial Update: HCV + to HCV - Kidney Transplant [Phase 4]
A Phase 4 clinical trial involving Hepatitis C and kidney failure in the context of kidney transplant was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2022-03-08Clinical Trial Update: Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access [Phase 4]
Clinical trial for a single-patient protocol involving donor HCV-positive to recipient HCV-negative kidney transplant was withdrawn.
-
EMA withdrawal · 2021-06-03EMA Withdrawn: PegIntron (peginterferon alfa-2b) — Merck Sharp & Dohme B.V.
EMA withdrew PegIntron (peginterferon alfa-2b) from the market for chronic hepatitis C.
-
CLINICAL_TRIALS withdrawal · 2021-05-06Clinical Trial Update: Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) [Phase 4]
Phase 4 trial for HCV infection titled ECLIPSE has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-01-29Clinical Trial Update: Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034) [Phase 3]
Phase 3 pediatric trial of boceprevir with peginterferon alfa-2b plus ribavirin for chronic hepatitis C genotype 1 was withdrawn.
-
EMA withdrawal · 2021-01-22EMA Withdrawn: ViraferonPeg (peginterferon alfa-2b) — Merck Sharp Dohme Ltd
EMA has withdrawn ViraferonPeg (peginterferon alfa-2b) by Merck Sharp & Dohme Ltd for chronic hepatitis C.
-
CLINICAL_TRIALS withdrawal · 2020-12-07Clinical Trial Update: Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet [Phase 4]
A Phase 4 bioequivalence study comparing crushed sofosbuvir/velpatasvir to the whole tablet was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-09-14Clinical Trial Update: HepATocellular Cancer Hcv Therapy Study [Phase 3]
Phase 3 trial for hepatocellular carcinoma/HCV therapy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-04-20Clinical Trial Update: Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 [Phase 4]
Phase 4 clinical trial targeting elimination of HCV infection in treatment-naïve, renally impaired Egyptian patients on dialysis has been wi…
-
CLINICAL_TRIALS withdrawal · 2020-02-26Clinical Trial Update: A Prospective Cohort Study to Improve HCV Care in Dialysis Patients [Phase 4]
Phase 4 prospective cohort study to improve hepatitis C care in dialysis patients was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-01-21Clinical Trial Update: HCV Post-Exposure Prophylaxis for Health Care Workers [Phase 4]
A Phase 4 clinical trial studying Hepatitis C post-exposure prophylaxis for healthcare workers was withdrawn.
-
EMA withdrawal · 2019-08-30EMA Expired: Daklinza (daclatasvir dihydrochloride) — Bristol-Myers Squibb Pharma EEIG
EMA indicates that Daklinza (daclatasvir dihydrochloride) has expired status as a medicinal product for chronic hepatitis C in the EU.
-
CLINICAL_TRIALS withdrawal · 2019-06-13Clinical Trial Update: A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C [Phase 4]
Phase 4 trial of simeprevir and sofosbuvir for HIV/Hepatitis C was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2019-06-03Clinical Trial Update: Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant [Phase 4]
A Phase 4 clinical trial evaluating direct-acting antiviral therapy for donor HCV-positive to recipient HCV-negative kidney transplants has …
-
CLINICAL_TRIALS withdrawal · 2019-01-23Clinical Trial Update: TG4040 in Patients With Chronic HCV [Phase 1]
A Phase 1 clinical trial of TG4040 for chronic Hepatitis C has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-12-20Clinical Trial Update: Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant [Phase 4]
A Phase 4 trial evaluating direct-acting antiviral therapy to prevent HCV infection in HCV-positive donor to HCV-negative recipient kidney t…
-
CLINICAL_TRIALS withdrawal · 2018-12-20Clinical Trial Update: Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant [Phase 4]
Clinical trial on preemptive Zepatier treatment in HCV-positive donors to HCV-negative recipients in cardiac transplant was withdrawn (Phase…
-
CLINICAL_TRIALS withdrawal · 2018-08-07Clinical Trial Update: A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk [Phase 4]
A Phase 4 single-arm study evaluating the effect of hepatitis C treatment on cardiovascular disease risk has been withdrawn.
-
EMA withdrawal · 2018-07-31EMA Withdrawn: Victrelis (Boceprevir) — Merck Sharp Dohme Ltd
EMA has withdrawn Victrelis (boceprevir) from the market in the EU.
-
CLINICAL_TRIALS withdrawal · 2018-06-08Clinical Trial Update: A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A [Phase 4]
Phase 4 retreatment trial evaluating elbasvir/grazoprevir plus sofosbuvir and ribavirin in chronic hepatitis C genotypes 1 and 4 patients wh…
-
EMA withdrawal · 2018-05-23EMA Withdrawn: Olysio (simeprevir) — Janssen-Cilag International NV
Olysio (simeprevir) has been withdrawn from the market by Janssen-Cilag International NV in relation to chronic hepatitis C.